FrancophonIA/ELRC3.0 huggingface dataset:
English: You must contact your doctor immediately if you experience any of the following symptoms of allergic reactions: swelling of the face, rash, generalised itching, hives, tightness of the chest, difficulty breathing, burning and stinging at the injection site, chills, flushing, headache, general feeling of being unwell, nausea, restlessness, fast heartbeat, and low blood pressure.
Maltese: Għandek tikkuntattja lit-tabib tiegħek immedjatament jekk ikollok kwalunkwe minn dawn is-sintomi li ġejjin ta' reazzjonijiet allerġiċi: nefħa tal-wiċċ, raxx, ħakk ġeneralizzat, ħorriqija, tagħfis tas-sider, diffikultà biex tieħu nifs, ħruq u tingiż fis-sit tal-injezzjoni, tertir ta' bard, fwawar, uġigħ ta' ras, tħossok ma tiflaħx b'mod ġenerali, dardir, nuqqas ta' kwiet f'ġismek, taħbit mgħaġġel tal-qalb, u pressjoni baxxa tad-demm.
English: Table 5 presents the pharmacokinetic parameters calculated from the paediatric data of 35 subjects less than 18 years of age.
Maltese: tippreżenta l-parametri farmakokinetiċi kkalkulati mid-dejta pedjatrika ta' 35 individwu li kellhom inqas minn 18-il sena.
English: How to store ALPROLIX
Maltese: X'fih ALPROLIX
English: In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk.
Maltese: F'pazjenti b'fatturi ta' riskju kardjovaskulari eżistenti, terapija ta' sostituzzjoni b'FIX tista' żżid ir-riskju kardjovaskulari.
English: Haemophilia B is an X-linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma.
Maltese: Emofilija B hi disturb ereditarju tal-koagulazzjoni tad-demm assoċjat ma' X, minħabba livelli mnaqqsa ta' fattur IX u tirriżulta fi ħruġ ta' demm fil-ġogi, fil-muskoli jew fl-organi interni, li jkun jew spontanju jew b'riżultat ta' trawma aċċidentali jew kirurġika.
English: No bleeding episodes were experienced in 42% of subjects while on individualised prophylaxis and in 23% of subjects while on weekly prophylaxis.
Maltese: L-ebda episodji ta' ħruġ ta' demm ma seħħew fi 42% tal-individwi waqt li kienu fuq profilassi individwalizzata, u fi 23.0% tal-individwi waqt li kienu fuq profilassi ta' kull ġimgħa.
English: CL (mL/h/kg)
Maltese: MRT (sigħat) CL (mL/siegħa/kg) Vss (mL/kg)
English: With the exception of one patient whose last prescribed dose was 100 IU/kg every 5 days, the other 29 patients last prescribed doses were up to 70 IU/kg every 7 days.
Maltese: Bl-eċċezzjoni ta' pazjent wieħed li l-aħħar doża preskritta tiegħu kienet ta' 100 IU/kg kull 5 ijiem, l-aħħar dożi preskritti tad-29 pazjent l-oħrajn kienu sa 70 IU/kg kull 7 ijiem.
English: It is a high purity factor product produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line, without the addition of any exogenous human- or animal-derived protein in the cell culture, purification or final formulation.
Maltese: Hu prodott ta' fattur ta' purità għolja magħmul permezz ta' teknoloġija tadDNA rikombinanti f'razza ta' ċelluli ta' kliewi embrijoniċi tal-bniedem (human embryonic kidney - HEK) mingħajr iż-żieda ta' kwalunkwe proteina esoġena derivata mill-bniedem jew mill-annimali fil-kultura taċ-ċelluli, purifikazzjoni jew formulazzjoni finali.
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Maltese: - stikk(ek) - pad(s) tal-garża.
English: Intravenous use.
Maltese: attività FIX endoġena).
English: Activated factor IX, in combination with activated factor VIII, activates factor X. Activated factor X converts prothrombin into thrombin.
Maltese: Fattur X attivat jibdel prothrombin għal thrombin.
English: The calculation of the required dose of recombinant factor IX Fc is based on the empirical finding that 1 International Unit (IU) factor IX per kg body weight raises the plasma factor IX activity by 1% of normal activity (IU/dL).
Maltese: Internazzjonali (IU) waħda ta' fattur IX għal kull kg ta' piż tal-ġisem tgħolli l-attività ta' fattur IX fil plażma b'1% tal-attività normali (IU/dL).
English: Turn the plunger rod firmly clockwise until it is securely seated in the syringe plunger.
Maltese: (clockwise) sakemm tkun f'postha b'mod sigur ġol-planġer tas siringa.
English: After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Maltese: Wara kura ripetuta bi prodotti li fihom fattur IX tal-koagulazzjoni uman, il-pazjenti għandhom jiġu mmonitorjati għall-iżvilupp ta' antikorpi newtralizzanti (inibituri) li għandhom jiġu kkwantifikati f'Unitajiet Bethesda (BUs) billi jintuża ttestjar bijoloġiku adattat.
English: The observed mean (SD) activity time profile following a single dose of ALPROLIX in patients with severe haemophilia B is shown below (see Table 4).
Maltese: tal-profil tal-attività u l-ħin wara doża waħda ta' ALPROLIX f'pazjenti b'emofilija B severa qed jintwera hawn taħt (ara Tabella 4).
English: ALPROLIX 1000 IU powder and solvent for solution for injection Each vial contains nominally 1000 IU eftrenonacog alfa.
Maltese: IU trab u solvent għal soluzzjoni għall-injezzjoni ALPROLIX 1000
English: One International Unit (IU) of recombinant factor IX Fc activity is equivalent to that quantity of factor IX in one mL of normal human plasma.
Maltese: Unità Internazzjonali (IU) waħda ta' attività ta' fattur IX rikombinanti Fc hi ekwivalenti għal dik ilkwantità ta' fattur IX f'mL wieħed ta' plażma normali tal-bniedem.
English: ALPROLIX 500 IU powder and solvent for solution for injection Each vial contains nominally 500 IU eftrenonacog alfa.
Maltese: IU trab u solvent għal soluzzjoni għall-injezzjoni ALPROLIX 500
English: The median average dose per injection to treat a bleeding episode was 63.51 (interquartile range, 48.9299.44) IU/kg.
Maltese: Il-medjan tad-doża medja għal kull injezzjoni biex jiġi kkurat episodju ta' ħruġ ta' demm kien ta' 63.51 (medda interkwartili 48.92-99.
English: After preparation, ALPROLIX can be stored at room temperature for up to 6 hours before administration.
Maltese: Wara l-preparazjoni, ALPROLIX jista' jinħażen fit-temperatura tal-kamra għal sa 6 sigħat qabel lgħoti.
English: Non-clinical data reveal no special hazard for humans based on thrombogenicity test in rabbits (Wessler stasis model) and repeated dose toxicity studies (which included assessment of local toxicity, male reproductive organs and electrocardiographic parameters) in rats and monkeys.
Maltese: effett tossiku minn dożi u ripetuti (li kienu jinkludu evalwazzjoni ta' tossiċità lokali, organi riproduttivi tal-irġiel u parametri elettrokardjografiċi) fil-firien u fix-xadini, ma juri l-ebda periklu speċjali għallbnedmin.
English: 3h
Maltese: IU 1000
English: ALPROLIX contains the active substance eftrenonacog alfa, recombinant coagulation factor IX, Fc fusion protein.
Maltese: IU trab u solvent għal soluzzjoni għall-injezzjoni eftrenonacog alfa fattur tal-koagulazzjoni IX rikombinanti, proteina tal-fużjoni Fc
English: In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity level (in % of normal or IU/dL) in the corresponding period.
Maltese: attività ta' plażma mogħti (f'% tan-normal jew f'IU/dL) fil-perjodu korrispondenti.
English: Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock).
Maltese: Sensittività eċċessiva jew reazzjonijiet allerġiċi (li jistgħu jinkludu anġjoedema, ħruq u tingiż fis-sit talinfużjoni, tertir ta' bard, fwawar, urtikarja ġeneralizzata, uġigħ ta' ras, ħorriqija, pressjoni baxxa, letarġija,
English: F) 2 Alcohol swabs G) 2 Plasters
Maltese: Ċ) Lasta tal-planġer waħda D) Adapter tal-kunjett wieħed E) Sett tal-infużjoni wieħed F) 2 Biċċiet bl-alkoħol
English: Repeat injection after 24 hours, as needed until healing is achieved1.
Maltese: Irrepeti l-injezzjoni wara 24 siegħa, skont ilħtieġa sakemm jinkiseb il-fejqan 1.
English: How ALPROLIX works
Maltese: ALPROLIX 1000
English: No interactions of ALPROLIX with other medicinal products have been reported.
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni L-ebda interazzjoni ta' ALPROLIX ma' prodotti mediċinali oħra ma ġiet irrapportata.
English: Incremental Recovery (IU/dL per IU/kg) AUC/Dose (IU*h/dL per IU/kg)
Maltese: Irkupru Inkrementali (IU/dL kull IU/kg)
English: Discard the vial and the adapter.
Maltese: IU ta' eftrenonacog alfa.
English: After this time, the prepared ALPROLIX should be discarded.
Maltese: Iċċekkja d data ta' skadenza fuq il-kartuna ta' ALPROLIX.
English: Attach the plunger rod (C) to the solvent syringe by inserting the tip of the plunger rod into the opening in the syringe plunger.
Maltese: demm fl-awrina (ematurija), uġigħ f'ġenbejk (kolika tal-kliewi), pressjoni tad-demm baxxa u tnaqqis flaptit.
English: Median annualised bleeding rates in subjects <12 years of age evaluable for efficacy were 1.97 (interquartile range 0.00-3.13) in Study II and remained similar throughout Study III (extension study).
Maltese: Ir-rati medjani annwalizzati ta' ħruġ ta' demm (median annualised bleeding rates) f'individwi li kellhom <12-il sena evalwabbli għall-effikaċja kienu ta' 1.97 (medda interkwartili ta' 0.00-3.13) fi Studju II u baqgħu simili matul Studju III (studju ta' estensjoni).
English: All pharmacokinetic studies with ALPROLIX were conducted in previously treated patients with severe haemophilia B. Data presented in this section were obtained by one-stage clotting assay with a silica-based aPTT reagent calibrated against factor IX plasma standards.
Maltese: Dejta ppreżentata f'din is-sezzjoni inkisbet permezz ta' assays tat-tagħqid tad-demm ta' stadju wieħed b'reaġent aPTT ibbażat fuq is-silica, ikkalibrat kontra standards ta' fattur IX tal-plażma.
English: All of the 30 patients were treated with ALPROLIX on a prophylactic dosing regimen starting with 50-60 IU/kg every 7 days, with adjustment of dose to a maximum of 100 IU/kg and dosing interval to a minimum of once weekly and a maximum of twice weekly.
Maltese: IU/kg kull 7 tijiem, b'aġġustament fid-doża għal massimu ta' 100 IU/kg, u intervall tad-dożaġġ għal minimu ta' darba fil-ġimgħa u massimu ta' darbtejn fil-ġimgħa.
English: 10 mins 1h
Maltese: 6 xhur.
English: Factor IX is activated by factor XIa in the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway.
Maltese: Dan hu ta' importanza partikulari meta jinbidel il-laboratorju u/jew ir-reaġent li jintużaw fl-analiżi.
English: The median average dose per injection to treat a bleeding episode was 46.07 (IQR: 32.86-57.03) IU/kg.
Maltese: 32.86-57.03) IU/kg.
English: The use of high purity factor IX is rarely associated with thromboembolic complications.
Maltese: L-użu ta' fattur IX b'purità għolja rari jkun assoċjat ma' kumplikazzjonijiet tromboemboliċi.
English: There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions.
Maltese: Kien hemm rapporti fil-letteratura li urew korrelazzjoni bejn l-okkorrenza ta' inibitur ta' fattur IX u reazzjonijiet allerġiċi.
English: Protect the solution from direct sunlight.
Maltese: Ilqa' s-soluzzjoni minn xemx diretta.
English: The haemostatic response was rated as excellent or good in 100% of major surgeries.
Maltese: Ir-rispons emostatiku ġie kklassifikat bħala eċċellenti jew tajjeb f'100% tal-operazzjonijiet maġġuri.
English: The terminal elimination half-life (t1/2) ranged from 7.3 hours to 8.6 hours, with mean value 7.7 hours.
Maltese: Il-half life (t1/2) tal-eliminazzjoni terminali varjat minn 7.3 sigħat sa 8.6 sigħat, b'valur medju ta' 7.7 sigħat.
English: ATCvet code: QC09CA07
Maltese: QC09CA07
English: See section “Contraindications”.
Maltese: Ara sezzjoni “Kontraindikazzjonijiet”.
English: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY
Maltese: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
English: The glucuronidation resulted in the formation of the 1-O-acylglucuronide metabolite of telmisartan.
Maltese: Il-glukoronidazzjoni rriżultat fil-formazzjoni tal-metabolit 1-O-acylglucuronide ta' telmisartan.
English: The target SBP range is between 120 and 140 mmHg.
Maltese: Il-firxa ta' SBP immirata hija bejn 120 u 140 mmHg.
English: Benzalkonium chloride Hydroxyethylcellulose Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Maltitol
Maltese: Hydroxyethylcellulose Sodium hydroxide (għal aġġustament tal-pH) Hydrochloric acid (għall-aġġustament tal-pH) Maltitol
English: Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, plain.
Maltese: Aġenti li jaġixxu fuq is-sistema renin-angiotensin, antagonisti ta' angiotensin II, sempliċi.
English: From in vitro and ex vivo studies with feline liver microsomes it can be concluded that telmisartan is effectively glucuronidated in the cat.
Maltese: Minn studji in vitro u ex vivo b'mikrosomi tal-fwied tal-qtates, wieħed jista' jikkonkludi li telmisartan jiġi glukoronidazzat b'mod effettiv filqtates.
English: In a European clinical field study, adverse events categorised as renal disorder/insufficiency (includes cases of chronic renal failure, elevated creatinine and/or blood urea nitrogen) were recorded in 3.6% of telmisartan-treated cats and 1% of placebo-treated cats.
Maltese: Fi studju kliniku Ewropew imwettaq f'ambjent naturali, avvenimenti avversi kklassifikati bħala disturb/insuffiċjenza tal-kliewi (inklużi każijiet ta' insuffiċjenza kronika tal-kliewi, kreatinina u/jew urea nitrogen fid-demm elevati) ġew irreġistrati fi 3.6% tal-qtates ittrattati b'telmisartan u f'1% talqtates ittrattati bi plaċebo.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali trattati li juru effetti mhux mixtieqa) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal trattat ) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal trattat ) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal trattat) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: The absolute bioavailability after oral administration was found to be 33%.
Maltese: Instab li lbijodisponibilità assoluta wara l-għoti orali hi ta' madwar 33%.
English: Telmisartan is metabolised by conjugation to the glucuronide of the parent compound.
Maltese: Telmisartan jiġi metabolizzat permezz ta' konjugazzjoni għal glucuronide tal-kompost prinċipali.
English: Shelf life of the veterinary medicinal product as packaged for sale (30 ml or 100 ml): 3 years.
Maltese: Żmien kemm idum tajjeb il-prodott mediċinali veterinarju kif ippakkjat għall-bejgħ (30 ml jew 100 ml): 3 snin.
English: Pack sizes of one plastic bottle filled with 30 ml or one plastic bottle filled with 100 ml.
Maltese: Daqsijiet tal-pakkett ta' flixkun tal-plastik wieħed mimli bi 30 ml jew flixkun tal-plastik wieħed mimli bi 100 ml.
English: After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinarian.
Maltese: Wara 4 ġimgħat, id-dożaġġ ta' telmisartan jista' jitnaqqas fi qtates bi pressjoni sistolika tad-demm (SBP - systolic blood pressure) ta' inqas minn 140 mmHg (f'żidiet ta' 0.5 mg/kg) skont iddiskrezzjoni tal-veterinarju.
English: The recommended dose is 1 mg telmisartan/kg body weight (0.25 ml/kg body weight).
Maltese: Id-doża rakkomandata hi ta' 1 mg ta' telmisartan/kg piż tal-ġisem (0.25 ml/kg piż tal-ġisem).
English: People with hypersensitivity to telmisartan or other sartans/ARBs should avoid contact with the veterinary medicinal product.
Maltese: Nies li huma sensittivi għal telmisartan jew sartans/ARBs oħrajn għandhom jevitaw li jmissu malprodott mediċinali veterinarju.
English: The initial recommended dose is 2 mg telmisartan/kg body weight (0.2 ml/kg body weight).
Maltese: Id-doża rakkomandata fil-bidu hi ta' 2 mg ta' telmisartan/kg piż tal-ġisem (0.2 ml/kg piż tal-ġisem).
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products.
Maltese: Fin-nuqqas ta' studji dwar kompatibilità, dan il-prodott mediċinali veterinarju ma jistax jintuża flimkien ma' prodotti mediċinali veterinarji oħra.
English: 35 ml 1 measuring syringe
Maltese: 35 ml siringa 1 tal-kejl
English: In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (>99.5%), mainly to albumin and α-1-acid glycoprotein.
Maltese: Studji in vitro fuq il-plażma tal-bniedem, il-kelb, il-ġurdien u l-far, urew twaħħil qawwi tal-proteini fil-plażma (>99.5%), primarjament mal-albumina u α-1-acid glycoprotein.
English: Telmisartan displaces angiotensin II from its binding site at the AT1 receptor subtype.
Maltese: Telmisartan jieħu post angiotensin II mis-sit fejn jeħel fis-sottotip tar-riċettur AT1.
English: The safety and efficacy of telmisartan for the management of systemic hypertension above 200 mmHg has not been investigated.
Maltese: Is-sigurtà u l-effikaċja ta' telmisartan għall-immaniġġjar ta' pressjoni sistemika għolja 'l fuq minn 200 mmHg ma ġewx investigati.
English: Stimulation of the AT1 receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis, organ remodelling and proteinuria.
Maltese: L-istimulazzjoni ta' riċettur AT1 hi responsabbli għall-effetti patoloġiċi ta' angiotensin II fil-kliewi u f'organi oħrajn assoċjati ma' angiotensin II bħal tidjiq fil-vini/arterji, żamma ta' sodium u ilma, żieda fis-sintesi ta' aldosterone, immudellar mill-ġdid tal-organi u proteina fl-awrina.
English: Treatment of systemic hypertension in cats.
Maltese: Trattament ta' pressjoni sistemika għolja fil-qtates.
English: Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEis), have been found to affect the unborn child during pregnancy in humans.
Maltese: Nisa tqal għandhom joqogħdu attenti b'mod speċjali biex jevitaw kuntatt mal-prodott għax sustanzi li jaġixxu fuq ir-RAAS, bħal Angiotensin Receptor Blockers (ARBs) u ACE inhibitors (ACEis), instab li jaffettwaw lit-tarbija mhux imwielda waqt it-tqala fil-bnedmin.
English: No clinically relevant accumulation was observed following multiple dose administration once daily for 21 days.
Maltese: L-ebda akkumulazzjoni klinikament rilevanti ma ġiet osservata wara għoti multipla tad-doża darba kuljum għal 21 jum.
English: See section “Pregnancy and lactation”.
Maltese: Ara sezzjoni “Tqala u treddigħ”.
English: Active substance: Telmisartan
Maltese: DIKJARAZZJONI TAS-SUSTANZA ATTIVA
English: Telmisartan does not exhibit any partial agonist activity at the AT1 receptor.
Maltese: Telmisartan ma jesibixxi l-ebda attività agonista parzjali fir-riċettur tip AT1.
English: The dosage of telmisartan should be reduced if systolic blood pressure (SBP) is consistently lower than 120 mmHg or if there are concurrent signs of hypotension.
Maltese: Id-dożaġġ ta' telmisartan għandu jitnaqqas jekk il-pressjoni sistolika tad-demm (SBP - systolic blood pressure) tkun b'mod konsistenti inqas minn 120 mmHg jew jekk ikun hemm sinjali fl-istess waqt ta' pressjoni baxxa.
English: Following oral administration of 1 mg/kg body weight telmisartan to cats, plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax).
Maltese: Wara l-għoti orali ta' telmisartan lil qtates, il-kurvi tal-konċentrazzjoni fil-plażma/ħin tal-kompost prinċipali huma kkaratterizzati minn assorbiment mgħaġġel b'konċentrazzjonijiet massimi fil-plażma (Cmax) li jintlaħqu wara 0.5 sigħat (tmax).
English: One HDPE bottle filled with 30 ml or 100 ml.
Maltese: Flixkun wieħed tal-HDPE mimli bi 30 ml jew 100 ml.
English: Telmisartan is highly lipophilic and has rapid membrane permeability kinetics, which facilitates easy distribution into tissue.
Maltese: Telmisartan hu lipofiliku ħafna u għandu kinetika tal-permeabilità mgħaġġla ħafna fil-membrani, u dan jiffaċilta d-distribuzzjoni ġot-tessut.
English: Pack size of one plastic bottle filled with 35 ml and one measuring syringe.
Maltese: TAGĦRIF IEĦOR Daqs tal-pakkett ta' flixkun tal-plastik wieħed mimli b'35 ml u siringa tal-kejl waħda.
English: Stimulation of the AT1 receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis and organ remodelling.
Maltese: L-istimulazzjoni ta' riċettur AT1 hi responsabbli għall-effetti patoloġiċi ta' angiotensin II fil-kliewi u f'organi oħrajn assoċjati ma' angiotensin II bħal tidjiq fil-vini/arterji, żamma ta' sodium u ilma, żieda fis-sintesi ta' aldosterone u immudellar mill-ġdid tal-organi.
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Maltese: DOŻA GĦAL KULL SPEĊI, MOD U METODU TA' AMMINISTRAZZJONI
English: Carton for 35 ml
Maltese: Flixkun għal 35 ml
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Maltese: METODU U MOD TA' AMMINISTRAZZJONI
English: Elevated liver enzymes have been very rarely observed and values normalised within a few days following cessation of therapy.
Maltese: Livelli ogħla ta' enzimi tal-fwied kienu osservati b'mod rari ħafna u l-valuri nnormalizzaw fi żmien ftit ijiem wara l-waqfien tat-terapija.
English: Very limited data are available regarding interactions in cats with hypertension between telmisartan and other medicinal products that lower blood pressure (such as amlodipine) or interfere with the RAAS (such as ARBs or ACEis).
Maltese: Hemm dejta limitata ħafna disponibbli dwar interazzjonijiet fi qtates bi pressjoni għolja bejn telmisartan u prodotti mediċinali oħra li jnaqqsu l-pressjoni tad-demm (bħal amlodipine) jew li jinterferixxu mal-RAAS (bħal ARBs jew ACEis).
English: Bottle for 30 ml
Maltese: Kunjett, 30 ml
English: In a clinical trial in cats with chronic kidney disease, a reduction in proteinuria was seen within the first 7 days after the start of treatment with 1 mg/kg.
Maltese: Fi prova klinika fil-qtates b'mard kroniku tal-kliewi, tnaqqis fi proteinurija ġie osservat fi żmien l-ewwel 7 ijiem mill-bidu tat-trattament b'1 mg/kg.
English: During concomitant therapy with amlodipine at the recommended dose for the reduction of proteinuria associated with chronic kidney disease (CKD) in cats no clinical evidence of hypotension was observed.
Maltese: Matul terapija fl-istess ħin ma' amlodipine fid-doża rakkomandata għat-tnaqqis ta' proteina fl-awrina assoċjata ma' marda kronika tal-kliewi (CKD - chronic kidney disease) fil-qtates ma ġiet osservata lebda evidenza klinika ta' pressjoni baxxa.
English: For both, Cmax-values, and AUC-values, a dose proportional increase over the dose range from 0.5 mg/kg to 3 mg/kg was observed.
Maltese: Għat-tnejn, il-valuri ta' Cmax u l-valuri ta' AUC ġew osservati li żdiedu proporzjonalment mad-doża fuq il-medda tad-doża minn 0.5 mg sa 3 mg/kg.